Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2019

View Archived Issues

Repair enables regeneration for blood vessels

Prelude Therapeutics initiates phase I study of PRT-543 in advanced malignancies

Phase I results of pegargiminase, cisplatin and pemetrexed in ASS1-deficient high-grade glioma

Discovery and characterization of a novel selective LMP7 inhibitor for multiple myeloma

Novel bispecific T-cell engager CAR therapy overcomes glioblastoma heterogeneity

GlaxoSmithKline presents preclinical data for GSK-102

Development of new long-term animal model of Graves' disease verified

Enrollment open in phase IIb study of dalcinonacog alfa for hemophilia B

Theralase's phase Ib study of TLD-1433 shows 66% CR at therapeutic dose 360 days post treatment

ViGenCell opens enrollment in phase II trial of VT-EBV-N for EBV-positive patients with ENKL

BioArctic receives grant for collaborative research to improve immunotherapy for CNS disorders

Pfizer begins phase I study of PF-06939999 in advanced or metastatic solid tumors

European Commission approves Vizimpro for first-line treatment of EGFR-mutated NSCLC

Daiichi Sankyo presents oral TIP48/TIP49 inhibitors for the treatment of hematological cancer

TUL-001 potently inhibits tumor growth in NSCLC brain metastasis model

Sangamo provides clinical development update

Stem cell-derived human 'hearts' identify new cardiac drugs

Shenzhen Biocan Technologies patents APP-targeting shRNAs

Shenzhen Biocan Technologies identifies new IDO-targeting shRNAs

TNFRSF18-targeting shRNAs described in Shenzhen Biocan Technologies patent

U.S. researchers synthesize antisense oligonucleotides targeting MYC

Bluevalley Pharmaceutical discloses ATR inhibitors

Preclinical results of EI-1071, a selective CSF1R inhibitor regulating tumor-associated macrophages

Comparison of the novel biguanide NT-1195 with metformin/phenformin in endometrial cancer models

Phase I results of highly selective dual IDO1/TDO2 inhibitor M-4112 in advanced solid malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...